SCHEMBL1663637

SCHEMBL1663637

COC(=O)c1ccc(-n2c(C(C)C)nc3cc(O)ccc3c2=O)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.65
ESR1 P03372 2/20 0.55
ESR2 Q92731 1/20 0.55
POLB P06746 1/20 0.54
ALDH1A1 P00352 7/20 0.46
KDM4E B2RXH2 4/20 0.46
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MAPT P10636 2/20 0.46
TSHR P16473 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
AKR1B1 P15121 1/20 0.42
CRBN Q96SW2 1/20 0.42
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1663409 0.85 TRPV1 (0.69) TRPV1ESR1ESR2ALDH1A1KDM4E
SCHEMBL1664439 0.83 TRPV1 (0.74) TRPV1ESR1ESR2POLBALDH1A1
SCHEMBL1663333 0.82 TRPV1 (0.69) TRPV1ESR1ESR2ALDH1A1LMNA
SCHEMBL1663398 0.82 TRPV1 (0.72) TRPV1ESR1ESR2ALDH1A1KDM4E
SCHEMBL1664011 0.82 TRPV1 (0.72) TRPV1ESR1ESR2POLBALDH1A1
SCHEMBL1665294 0.81 TRPV1 (0.70) TRPV1ESR1ESR2ALDH1A1LMNA
SCHEMBL1666166 0.79 TRPV1 (0.51) TRPV1ESR1ESR2POLBALDH1A1
SCHEMBL10445948 0.79 TRPV1 (0.68) TRPV1ESR1ESR2KCNH2HRH3
SCHEMBL1066896 0.79 TRPV1 (1.00) TRPV1ESR1ESR2KMT2AKCNH2
SCHEMBL14752483 0.79 TRPV1 (0.79) TRPV1ESR1ESR2POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 TRPV1 1/4885ESR1 1321/4885ESR2 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.